Patents by Inventor Eric J. Niesor

Eric J. Niesor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CETP inhibitors for therapeutic use
    Patent number: 11549142
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: January 10, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • CETP INHIBITORS FOR THERAPEUTIC USE
    Publication number: 20210017597
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: June 3, 2020
    Publication date: January 21, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-PIerre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • CETP inhibitors for therapeutic use
    Patent number: 10711303
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: July 14, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • CETP INHIBITORS FOR THERAPEUTIC USE
    Publication number: 20190226020
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: August 22, 2018
    Publication date: July 25, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • CETP MODULATOR FOR USE IN THE TREATEMENT OF EYE DISEASE
    Publication number: 20190224147
    Abstract: The invention relates CETP modulator which is useful in the prevention, treatment, delaying progression and/or reduction of eye diseases.
    Type: Application
    Filed: April 3, 2019
    Publication date: July 25, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Evelyne Chesne, Eric J. Niesor
  • CETP INHIBITORS FOR THERAPEUTIC USE
    Publication number: 20180155784
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: January 22, 2018
    Publication date: June 7, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Dalcetrapib for therapeutic use
    Patent number: 9909178
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: March 6, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • BIOMARKERS AND METHODS OF PREDICTION
    Publication number: 20170322225
    Abstract: Subject of the present invention are biomarkers and methods for the identification of risk for subsequent cardiovascular event (e.g. coronary heart disease death, non-fatal myocardial infarction, ischemic stroke, hospitalizations for unstable angina pectotis, cardiac arrest) in patients that have experienced an acute coronary syndrome, comprising the detecting the level of NT-proBNP, homocysteine and CRP.
    Type: Application
    Filed: April 21, 2017
    Publication date: November 9, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas Dieterle, Eric J. Niesor, Rosemarie Kientsch-Engel, Horst Klima, Fabian Model, Gabriela Bucklar, Vinzent Rolny
  • CETP MODULATOR FOR USE IN THE TREATEMENT OF EYE DISEASE
    Publication number: 20160287537
    Abstract: The present invention relates CETP modulator which is useful in the prevention, treatment, delaying progression and/or reduction of eye diseases.
    Type: Application
    Filed: June 7, 2016
    Publication date: October 6, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Evelyne Chesne, Eric J. Niesor
  • GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY
    Publication number: 20160244826
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: September 23, 2015
    Publication date: August 25, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Compounds
    Patent number: 8178583
    Abstract: The invention is concerned with compounds of formula I: wherein R, R2, and Q are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are useful as inhibitors of cholesteryl ester transfer protein (CETP).
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: May 15, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Torsten Hoffmann, Holger Kuehne, Eric J. Niesor, Philippe Pflieger
  • NOVEL COMPOUNDS
    Publication number: 20100160441
    Abstract: The invention is concerned with compounds of formula I: wherein R, R2, and Q are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are useful as inhibitors of cholesteryl ester transfer protein (CETP).
    Type: Application
    Filed: December 7, 2009
    Publication date: June 24, 2010
    Inventors: Torsten Hoffmann, Holger Kuehne, Eric J. Niesor, Philippe Pflieger
  • Benzimidazole derivatives
    Patent number: 7645785
    Abstract: The invention is concerned with novel benzimidazole derivatives of formula (I) wherein R1 to R8 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to Farnesoid-X-receptors (FXR) and can be used to treat diseases which are modulated by FXR agonists such as diabetes and dyslipidemia.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: January 12, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Gregory Martin Benson, Konrad Bleicher, Alexander Chucholowski, Henrietta Dehmlow, Uwe Grether, Bernd Kuhn, Rainer E. Martin, Eric J. Niesor, Narendra Panday, Hans Richter, Franz Schuler, Xavier Marie Warot, Matthew Wright, Minmin Yang